Glenmark Pharmaceuticals saw its share price hit the 10% upper circuit after announcing a major cancer drug licensing agreement with AbbVie. The deal has sparked bullish analyst sentiment, projecting strong future gains for the pharma giant.
Image: Business Standard
Glenmark Pharma Rockets 10% After AbbVie Licensing Deal
In a strong start to the trading week, Glenmark Pharmaceuticals surged nearly 10% in intraday trading on July 11, hitting its upper circuit on the BSE, after announcing a significant oncology licensing agreement with US-based pharma major AbbVie.
The agreement involves Glenmark’s innovative MEK 1/2 inhibitor (ISB 2001), developed through its subsidiary Ichnos Sciences, being licensed to AbbVie for development and commercialization. This deal not only validates Glenmark’s R&D capabilities in oncology but also ensures near-term cash inflows and long-term royalties, positioning the company for sustained growth.
Strategic Impact: A Turning Point for Glenmark
The AbbVie partnership is a major milestone for Glenmark’s innovation-focused subsidiary, Ichnos Sciences. AbbVie, known for its portfolio of advanced oncology drugs, will now take over the development of ISB 2001 globally. This collaboration allows Glenmark to unlock value from its biotech investments, which have often been undervalued by the market.
The deal is structured to include upfront and milestone-based payments (exact figures undisclosed), along with royalties on future sales. This development has been seen as cash-positive and margin-accretive in the long run.
Market Reaction and Analyst Views
Following the announcement, Glenmark’s stock surged to ₹1,082.15, hitting the upper circuit. Analysts at major brokerage firms upgraded the stock, citing the deal as a key trigger for valuation re-rating.
According to Motilal Oswal, the transaction adds both financial strength and strategic credibility to Glenmark’s innovation pipeline. Meanwhile, ICICI Securities noted that the company’s focus on monetizing research assets is finally bearing fruit, opening room for long-term upside.
What This Means for Investors
The deal offers a dual benefit to shareholders — immediate market re-rating and enhanced confidence in Glenmark’s ability to commercialize complex research assets. For retail investors, this could signal a good entry point given the momentum and pipeline visibility the AbbVie partnership offers.
With the pharma sector expected to see increased M&A and licensing activity, Glenmark’s move could inspire similar tie-ups from mid-cap pharma peers.
